Evidence map›Paper›PMID 31729540›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2020

In vivo characterization of [

Pavitra Kannan, András Füredi, Sabina Dizdarevic, Thomas Wanek, Severin Mairinger, Jeffrey Collins, Theresa Falls, R Michael van Dam, Divya Maheshwari, Jason T Lee and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Pavitra KannanCRUK and MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. pk@sciencesylt.com.ORCID 0000-0002-9170-6062
András FürediInstitute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Sabina DizdarevicBrighton and Sussex University Hospitals, NHS Trust and Brighton and Sussex Medical School, Brighton, UK.
Thomas WanekPreclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Severin MairingerPreclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Jeffrey CollinsCrump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Theresa FallsCrump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
R Michael van DamCrump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Divya MaheshwariAvaant Imaging, Lexington, MA, USA.
Jason T LeeCrump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Gergely SzakácsInstitute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Oliver LangerPreclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Austrian Institute of Technology · ATInstitute for Molecular Medicine · USInstitute of Molecular Life Sciences · HUBrighton and Sussex Medical School · GBKarolinska Institutet · SEStanford Medicine · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
NCI NIH HHS P30 CA016042
6 · The paper itself

Abstract

purposeMultidrug resistance (MDR) impedes cancer treatment. Two efflux transporters from the ATP-binding cassette (ABC) family, ABCB1 and ABCG2, may contribute to MDR by restricting the entry of therapeutic drugs into tumor cells. Although a higher expression of these transporters has been correlated with an unfavorable response to chemotherapy, transporter expression does not necessarily correlate with function. In this study, we characterized the pharmacological properties of [

methodsAVT-011 was radiolabeled with

resultsAt baseline, brain uptake was highest in Abcb1a/b

conclusion[

Indexed as

Drug Resistance, MultiplePositron-Emission TomographyAnimalsATP Binding Cassette Transporter, Subfamily G, Member 2Blood-Brain BarrierMiceTissue DistributionATP Binding Cassette Transporter, Subfamily G, Member 2ABCB1ABCG2CancerMultidrug resistancePET imaging

Identifiers

PMID31729540
PMCPMC7299908
OpenAlexW2988334317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.